Efficacy and safety of SGLT2 inhibitor, Ipragliflozin in type 2 diabetes patients.
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000013898
- Lead Sponsor
- Chubu-Rosai Hospital Department of Diabetes and Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 15
Not provided
1.Patient who had myocardial infarction within the past six months. 2.Patient with a severe ketotic diabetic coma or precoma. 3.Patient with severe infectious disease (especially urinary tract infection), before and after operation, and a serious injury. 4.Patient with a past history of hypersensitivity for Ipragliflozin. 5.A pregnant woman or woman who may be pregnant. 6.Elderly person (>70 years). 7 Patient with hypoalimentation or dehydration. 8.Patient who is considered to be inappropriate by the chief physician. During the entire study period, when the chief physician judges that the continuing participation in this study became difficult, by aggravation such as HbA1c or blood glucose level and other factors, the appropriate treatment should be done immediately: administration of other antihyperglycemic agent or other appropriate measures.
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method